Bone Marrow-Derived Cells

From the Laboratory to the Clinic

J. Xie, K. L. March, Michael Murphy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Bone marrow mononuclear cells (BMMNC) are enriched with a variety of angiogenic stem and progenitor cells, as well as mature hematopoietic cells that function synergistically to promote neovascularization. Delivery of BMMNC or its subpopulations have demonstrated marked effects on revascularization of ischemic tissue in preclinical models. Extensive phase-I and -II clinical trials in critical limb ischemia (CLI) patients have established the safety of BMMNC and showed promising effects of the cells to improve ischemic pain, ulcer size, pain-free walking distance, ABI, and TcPO2, while phase-III randomized control trials (RCT) are rapidly unfolding. This chapter introduces the concept of BMMNC and its subpopulations in the context of peripheral arterial disease. It also discusses the animal models of CLI in which mechanisms of bone marrow-derived cells were investigated. Finally, the progress in the clinical trials using BMMNC to treat CLI patients were summarized and the challenges were discussed.

Original languageEnglish (US)
Title of host publicationRegenerative Medicine for Peripheral Artery Disease
PublisherElsevier Inc.
Pages27-42
Number of pages16
ISBN (Print)9780128013441
DOIs
StatePublished - Jun 13 2016

Fingerprint

Bone Marrow Cells
Bone
Ischemia
Extremities
Stem Cells
Phase II Clinical Trials
Clinical Trials, Phase I
Peripheral Arterial Disease
Ulcer
Walking
Animals
Animal Models
Clinical Trials
Tissue
Safety
Pain

Keywords

  • Animal model
  • Bone marrow mononuclear cell
  • Clinical trial
  • Endothelial progenitor cells
  • Hematopoietic stem cell
  • Peripheral arterial disease

ASJC Scopus subject areas

  • Engineering(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Xie, J., March, K. L., & Murphy, M. (2016). Bone Marrow-Derived Cells: From the Laboratory to the Clinic. In Regenerative Medicine for Peripheral Artery Disease (pp. 27-42). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-801344-1.00003-6

Bone Marrow-Derived Cells : From the Laboratory to the Clinic. / Xie, J.; March, K. L.; Murphy, Michael.

Regenerative Medicine for Peripheral Artery Disease. Elsevier Inc., 2016. p. 27-42.

Research output: Chapter in Book/Report/Conference proceedingChapter

Xie, J, March, KL & Murphy, M 2016, Bone Marrow-Derived Cells: From the Laboratory to the Clinic. in Regenerative Medicine for Peripheral Artery Disease. Elsevier Inc., pp. 27-42. https://doi.org/10.1016/B978-0-12-801344-1.00003-6
Xie J, March KL, Murphy M. Bone Marrow-Derived Cells: From the Laboratory to the Clinic. In Regenerative Medicine for Peripheral Artery Disease. Elsevier Inc. 2016. p. 27-42 https://doi.org/10.1016/B978-0-12-801344-1.00003-6
Xie, J. ; March, K. L. ; Murphy, Michael. / Bone Marrow-Derived Cells : From the Laboratory to the Clinic. Regenerative Medicine for Peripheral Artery Disease. Elsevier Inc., 2016. pp. 27-42
@inbook{902816cf650d4ef3b3596c37261c6f8a,
title = "Bone Marrow-Derived Cells: From the Laboratory to the Clinic",
abstract = "Bone marrow mononuclear cells (BMMNC) are enriched with a variety of angiogenic stem and progenitor cells, as well as mature hematopoietic cells that function synergistically to promote neovascularization. Delivery of BMMNC or its subpopulations have demonstrated marked effects on revascularization of ischemic tissue in preclinical models. Extensive phase-I and -II clinical trials in critical limb ischemia (CLI) patients have established the safety of BMMNC and showed promising effects of the cells to improve ischemic pain, ulcer size, pain-free walking distance, ABI, and TcPO2, while phase-III randomized control trials (RCT) are rapidly unfolding. This chapter introduces the concept of BMMNC and its subpopulations in the context of peripheral arterial disease. It also discusses the animal models of CLI in which mechanisms of bone marrow-derived cells were investigated. Finally, the progress in the clinical trials using BMMNC to treat CLI patients were summarized and the challenges were discussed.",
keywords = "Animal model, Bone marrow mononuclear cell, Clinical trial, Endothelial progenitor cells, Hematopoietic stem cell, Peripheral arterial disease",
author = "J. Xie and March, {K. L.} and Michael Murphy",
year = "2016",
month = "6",
day = "13",
doi = "10.1016/B978-0-12-801344-1.00003-6",
language = "English (US)",
isbn = "9780128013441",
pages = "27--42",
booktitle = "Regenerative Medicine for Peripheral Artery Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Bone Marrow-Derived Cells

T2 - From the Laboratory to the Clinic

AU - Xie, J.

AU - March, K. L.

AU - Murphy, Michael

PY - 2016/6/13

Y1 - 2016/6/13

N2 - Bone marrow mononuclear cells (BMMNC) are enriched with a variety of angiogenic stem and progenitor cells, as well as mature hematopoietic cells that function synergistically to promote neovascularization. Delivery of BMMNC or its subpopulations have demonstrated marked effects on revascularization of ischemic tissue in preclinical models. Extensive phase-I and -II clinical trials in critical limb ischemia (CLI) patients have established the safety of BMMNC and showed promising effects of the cells to improve ischemic pain, ulcer size, pain-free walking distance, ABI, and TcPO2, while phase-III randomized control trials (RCT) are rapidly unfolding. This chapter introduces the concept of BMMNC and its subpopulations in the context of peripheral arterial disease. It also discusses the animal models of CLI in which mechanisms of bone marrow-derived cells were investigated. Finally, the progress in the clinical trials using BMMNC to treat CLI patients were summarized and the challenges were discussed.

AB - Bone marrow mononuclear cells (BMMNC) are enriched with a variety of angiogenic stem and progenitor cells, as well as mature hematopoietic cells that function synergistically to promote neovascularization. Delivery of BMMNC or its subpopulations have demonstrated marked effects on revascularization of ischemic tissue in preclinical models. Extensive phase-I and -II clinical trials in critical limb ischemia (CLI) patients have established the safety of BMMNC and showed promising effects of the cells to improve ischemic pain, ulcer size, pain-free walking distance, ABI, and TcPO2, while phase-III randomized control trials (RCT) are rapidly unfolding. This chapter introduces the concept of BMMNC and its subpopulations in the context of peripheral arterial disease. It also discusses the animal models of CLI in which mechanisms of bone marrow-derived cells were investigated. Finally, the progress in the clinical trials using BMMNC to treat CLI patients were summarized and the challenges were discussed.

KW - Animal model

KW - Bone marrow mononuclear cell

KW - Clinical trial

KW - Endothelial progenitor cells

KW - Hematopoietic stem cell

KW - Peripheral arterial disease

UR - http://www.scopus.com/inward/record.url?scp=85013249561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013249561&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801344-1.00003-6

DO - 10.1016/B978-0-12-801344-1.00003-6

M3 - Chapter

SN - 9780128013441

SP - 27

EP - 42

BT - Regenerative Medicine for Peripheral Artery Disease

PB - Elsevier Inc.

ER -